Janux Therapeutics (NASDAQ:JANX) Receives “Outperform” Rating from William Blair

William Blair reaffirmed their outperform rating on shares of Janux Therapeutics (NASDAQ:JANX) in a research note published on Friday,RTT News reports.

A number of other analysts also recently issued reports on JANX. Leerink Partners lifted their target price on Janux Therapeutics from $79.00 to $91.00 and gave the company an “outperform” rating in a research report on Tuesday, December 3rd. Lifesci Capital raised Janux Therapeutics to a “strong-buy” rating in a research report on Friday, December 27th. Cantor Fitzgerald reissued an “overweight” rating and issued a $200.00 price objective on shares of Janux Therapeutics in a report on Wednesday, December 11th. Leerink Partnrs upgraded shares of Janux Therapeutics to a “strong-buy” rating in a report on Friday, November 22nd. Finally, Stifel Nicolaus lifted their price objective on shares of Janux Therapeutics from $70.00 to $115.00 and gave the company a “buy” rating in a research report on Tuesday, December 3rd. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $89.90.

Janux Therapeutics Stock Performance

NASDAQ JANX opened at $46.76 on Friday. Janux Therapeutics has a 52 week low of $7.79 and a 52 week high of $71.71. The stock’s 50 day moving average price is $54.26 and its two-hundred day moving average price is $48.20. The stock has a market capitalization of $2.45 billion, a price-to-earnings ratio of -39.97 and a beta of 3.23.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The business had revenue of $0.44 million during the quarter, compared to the consensus estimate of $1.50 million. Janux Therapeutics’s revenue was down 82.6% compared to the same quarter last year. On average, equities research analysts forecast that Janux Therapeutics will post -1.35 EPS for the current year.

Insider Transactions at Janux Therapeutics

In other Janux Therapeutics news, Director Ra Capital Management, L.P. acquired 1,200,000 shares of the business’s stock in a transaction on Friday, October 18th. The stock was purchased at an average price of $44.75 per share, with a total value of $53,700,000.00. Following the acquisition, the director now directly owns 9,317,246 shares of the company’s stock, valued at approximately $416,946,758.50. This trade represents a 14.78 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Ventures Xi L.P. Avalon sold 1,843 shares of the firm’s stock in a transaction that occurred on Thursday, October 17th. The stock was sold at an average price of $50.02, for a total transaction of $92,186.86. Following the transaction, the insider now directly owns 6,371 shares in the company, valued at $318,677.42. This represents a 22.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 110,177 shares of company stock worth $6,162,207 over the last quarter. Company insiders own 29.40% of the company’s stock.

Institutional Investors Weigh In On Janux Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp lifted its position in shares of Janux Therapeutics by 136.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 115,027 shares of the company’s stock valued at $4,818,000 after acquiring an additional 66,340 shares during the period. Principal Financial Group Inc. bought a new position in Janux Therapeutics in the 2nd quarter valued at about $237,000. Rhumbline Advisers raised its position in shares of Janux Therapeutics by 41.2% in the 2nd quarter. Rhumbline Advisers now owns 38,008 shares of the company’s stock valued at $1,592,000 after buying an additional 11,085 shares in the last quarter. TD Asset Management Inc bought a new stake in shares of Janux Therapeutics during the 2nd quarter worth approximately $829,000. Finally, Victory Capital Management Inc. acquired a new stake in shares of Janux Therapeutics during the 2nd quarter worth approximately $512,000. Institutional investors and hedge funds own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.